COVID-19 Vaccine Urgency Throws Spotlight on Next-Gen Sequencing as Key Facilitator

The urgency of delivering a vaccine for COVID-19 in previously unattainable timeframes and volumes is throwing the spotlight on the expanded role next-generation sequencing (NGS) needs to play to avoid the time delays and other limitations of in vivo/animal testing.  
PART II: Sanofi Pasteur and Ghent University Experience with NGS [CLICK HERE]

PART III: A Decade of Regulator/Industry Collaboration on NGS [CLICK HERE]
 

IPQ’s busy virtual meeting schedule through July includes:

 

IPQ Monthly Update – March 2020 in Review

The first story in the March Monthly Update explores recent FDA global field inspection and enforcement operations. In focus are: ● the impact of the pandemic ● the field office’s API and drug product inventory and enforcement tools ● recent warning letter and import alert data and trends, and ● progress on the goals of reducing the timelines for inspection classification/notification and warning letter issuance. The following story provides insights from FDA’s drug compliance management on the recent global developments and trends of significance across the API, OTC, sterile product, compounding, and supply chain arenas.

IPQ would like to thank our sponsors: